Subbiah V - Search Results

1

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.

Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Liu X, et al. Among authors: subbiah v. BMC Cancer. 2015 Oct 16;15:713. doi: 10.1186/s12885-015-1701-3. BMC Cancer. 2015. PMID: 26474549 Free PMC article.

2

Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.

Subbiah V, Trent JC, Kurzrock R. Subbiah V, et al. J Clin Oncol. 2010 Aug 20;28(24):e415. doi: 10.1200/JCO.2010.29.4678. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567010 No abstract available.

3

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.

Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R. Subbiah V, et al. PLoS One. 2011 Apr 6;6(4):e18424. doi: 10.1371/journal.pone.0018424. PLoS One. 2011. PMID: 21494688 Free PMC article.

4

Phase 1 clinical trials for sarcomas: the cutting edge.

Subbiah V, Kurzrock R. Subbiah V, et al. Curr Opin Oncol. 2011 Jul;23(4):352-60. doi: 10.1097/CCO.0b013e3283477a94. Curr Opin Oncol. 2011. PMID: 21519259 Review.

5

Gastric adenocarcinoma in children and adolescents.

Subbiah V, Varadhachary G, Herzog CE, Huh WW. Subbiah V, et al. Pediatr Blood Cancer. 2011 Sep;57(3):524-7. doi: 10.1002/pbc.23051. Epub 2011 Jan 24. Pediatr Blood Cancer. 2011. PMID: 21744476 Free PMC article.

6

Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?

Subbiah V, Angelo LS, Kurzrock R. Subbiah V, et al. Expert Opin Investig Drugs. 2011 Nov;20(11):1471-7. doi: 10.1517/13543784.2011.619978. Epub 2011 Sep 21. Expert Opin Investig Drugs. 2011. PMID: 21936711

7

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R. Subbiah V, et al. J Clin Oncol. 2012 Feb 10;30(5):e64-8. doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27. J Clin Oncol. 2012. PMID: 22203760 Free PMC article. Clinical Trial. No abstract available.

8

Ewing's sarcoma: overcoming the therapeutic plateau.

Subbiah V, Kurzrock R. Subbiah V, et al. Discov Med. 2012 Jun;13(73):405-15. Discov Med. 2012. PMID: 22742646 Free PMC article.

9

Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Subbiah V, et al. Mol Cancer Ther. 2012 Nov;11(11):2541-6. doi: 10.1158/1535-7163.MCT-12-0358. Epub 2012 Aug 20. Mol Cancer Ther. 2012. PMID: 22914439 Free PMC article.

10

A tale of two histiocytic disorders.

Janku F, Munoz J, Subbiah V, Kurzrock R. Janku F, et al. Among authors: subbiah v. Oncologist. 2013;18(1):2-4. doi: 10.1634/theoncologist.2012-0440. Epub 2013 Jan 8. Oncologist. 2013. PMID: 23299771 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

615 results

Search Page

Filters